Wuhan opens insulin belt purchase!

Recently, Wuhan pharmaceutical machinery centralized volume purchase service platform issued a notice on volume purchase and price negotiation of insulin drugs in Wuhan According to the notice, before January 9, the enterprises participating in the on-site negotiation need to complete the check-in; clear scope of drug purchase, grouping principle, price negotiation rules, quotation method, etc Among them, the scope of drug purchase: human insulin and insulin analogues drugs that are online in "Hubei provincial centralized purchasing service platform for medical devices" and have transaction volume in medical institutions in Wuhan before June 30, 2019; it is worth noting that in addition to the agreed purchase volume, the remaining purchase volume will be used as an alternative consumption, if the reduction and weighted reduction are not up to 5%, the product of the enterprise in 2018 More than 50% of the purchase volume in Wuhan area will be used as an alternative It is also clear in the document that in the same group, based on the absolute value of price reduction or weighted absolute value of price reduction, the top three enterprises are selected from the highest to the lowest to obtain the substitute consumption, the first enterprise gets 50% of the substitute consumption, the second enterprise gets 30%, and the third enterprise gets 20% of the substitute consumption In addition, the notice stipulates that patients who are using the non selected varieties will be given a three-month clinical substitution period According to the needs of patients, medical institutions at or above the second level can be selected to implement substitution according to the preferred use method of new patients under the guidance of doctors For non selected varieties that cannot be replaced due to clinical needs, the principle of "one patient one record" shall be followed The original text of the notice is as follows: 37